FDA Approves New Option in Obesity - Takeaways - MDSpire

FDA Approves New Option in Obesity

The Allurion Gastric Balloon System is now authorized by the US Food and Drug Administration for short-term weight loss in adults aged 22 to 65 years with obesity and a body mass index of 30 to 40 kg/m2.

  • By

  • Kathryn Wighton

  • February 23, 2026

  • 3 min

Share

  • 1

    The FDA approved the Allurion Gastric Balloon System, a swallowable device for obesity treatment without surgery or anesthesia.

  • 2

    The device is intended for adults aged 22 to 65 with obesity who have previously failed weight loss attempts.

  • 3

    The balloon remains in the stomach for about 4 months, promoting satiety and reducing caloric intake.

  • 4

    The Allurion Smart Capsule offers a safe alternative to glucagon-like peptide-1s and bariatric surgery.

  • 5

    In commercial settings outside the US, the device has shown an average total body weight loss of 14%.

Original Source(s)

FDA Approves New Option in Obesity

  • by Kathryn Wighton

  • February 23, 2026

Related Content

Case Report: First description of an intracranial “NET” in ROHHAD syndrome; time to rename to the ROHHAD-NeCT syndrome?

Ensitrelvir Reduced COVID After Household Exposure

In SCORPIO-PEP, symptomatic COVID-19 occurred in 3% vs 9% of household contacts by day 10.

Meta-inflammation in Hidradenitis suppurativa: from pathogenic evidence to therapeutic approaches